Clarifying the timeline for RAS activation, the status of NOS isoforms, and the relationship between these two systems in the vasculature of young SCH may provide insight into the etiology of cardiac deterioration, and contribute to the development of new therapeutic strategies for HF treatment. The gene discussed is NOS2; the disease is spindle cell hemangioma.